Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT01357967 Recruiting - Clinical trials for Major Depressive Disorder

The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope

Start date: May 2011
Phase: Phase 4
Study type: Interventional

Recently, there are increasing data about intensity dependent amplitude change (IDAP: N100 amplitude slope) of auditory evoked Event Related Potential (ERP) components for its role on surrogate marker of central serotonergic activity. A high N100 amplitude slope reflects low serotonergic neurotransmission and vice versa. There are a couple of studies reporting associations of N1 amplitude slope with response to Citalopram (positive correlation) and Reboxetine (negative correlation) treatment in major depressive disorder patients (2,3). The investigator also published a case series about SSRI super-sensitivity and SSRI induced mania in patients with aberrantly high N100 slope (4). And serotonin transporter gene polymorphism was studied for its role about pathophysiology of bipolar disorder (5, 6, 7). Serotonin promoter gene was known to have significant relationship with N100 amplitude slope (8). Furthermore previous study showed that N100 amplitude slope was well correlated with hypomanic and hyperthymic personality (9). Conclusively from above results, the investigator hypothesized that if depressive patients show aberrant high or low N100 amplitude slope (N100 response outliers), they will not response well to SSRI medication. They will response better to quetiapine XR adjunctive therapy. In this study, the investigator will confirm it by comparing treatment effect between SSRI monotherapy and quetiapine XR adjunctive in aberrant N100 responder. Hypothesis First visit depressive patients might have monopolar or bipolar depression. If depressive patients show aberrantly high or low N100 amplitude slope, they will not response to SSRI medication. Patients who have aberrantly high or low N100 amplitude slope will response better to quetiapine XR adjunctive therapy.

NCT ID: NCT01327417 Recruiting - Depression Clinical Trials

Late-Life Depression

Start date: September 2009
Phase: N/A
Study type: Observational

The purpose of the study is to examine the relationship between brain structure and depression in adults aged 60 or older. This relationship is determined using magnetic resonance imaging technology (MRI), a scanner with a magnet that is used to create images of the brain.

NCT ID: NCT01327404 Recruiting - Depression Clinical Trials

Depression in Type 2 Diabetes

Start date: October 2009
Phase: N/A
Study type: Observational

The purpose of the study is to examine the relationship between brain structure and depression in adults aged 30 or older with Diabetes. This relationship is determined using magnetic resonance imaging technology (MRI), a scanner with a magnet that is used to create images of the brain.

NCT ID: NCT01314521 Recruiting - Depression Clinical Trials

Suicidal Ideation and Behavior in Korean Adolescents With Depression

Start date: January 2011
Phase: N/A
Study type: Observational

The purpose of this study is to examine clinical characteristics of Korean adolescents with depression who have suicidal ideation and behavior. We formulate those hypotheses. 1. Being bullied in peer relationships, excessive use of internet, excessive extra-curricular tutoring, sexual abuse in childhood, physical abuse and emotional neglect are risk factors of suicide in adolescents. 2. Depression of parents and negative child-rearing attitude are risk factors of suicidal ideation and behavior in adolescents. 3. Emotional quotient (EQ) and resilience of adolescent are protective factors of suicide.

NCT ID: NCT01292499 Recruiting - Depression Clinical Trials

Italian Network for the Improvement of Compliance in Depression

Start date: March 2009
Phase: N/A
Study type: Interventional

The RIMAT‐De study (Rete Italiana per il Miglioramento dell'Adesione al Trattamento nella Depressione) is a multicentric Randomized Controlled Clinical Trial aiming at identifying the best strategies available to reduce the poor compliance of patients with antidepressant drugs. Patients' compliance will be measured within six months of pharmacological treatment, comparing the specific contributions of brief psychotherapy and psychoeducational interventions: the psychoeducational intervention will encompass the monitoring of drugs' side effects and patients' satisfaction. In the rest of the document, for the sake of brevity the two treatments previously described will be indicated as "psychotherapy" and "psychoeducation". These treatments will be compared with the treatment usually carried on by the mental health centers involved (i.e. treatment as usual, TAU). The factorial design of the study will take into consideration the combination of the two treatments (i.e. psychotherapy and psychoeducation) as well.

NCT ID: NCT01267773 Recruiting - Depression Clinical Trials

Treatment of Conduct Problems and Depression

Start date: August 2010
Phase: Phase 1
Study type: Interventional

Having both depression and conduct problems at the same time has been found to be associated with increased risk for the other and increased risk of negative outcomes. This study will develop an family based cognitive behavioral treatment protocol for youths with both conduct problems and depression, that will take be administered over the course of six months. Youth with comorbid conduct problems and depression will be assigned to the experimental condition or treatment as usual in a community care setting. The treatment manual will be revised as needed. Youth will be assessed before and after treatment to examine program potential. The goal of this research is to develop a more comprehensive outpatient treatment for youth with both conduct problems and depression.

NCT ID: NCT01260649 Recruiting - Clinical trials for Major Depressive Disorder

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

Start date: November 2010
Phase: Phase 4
Study type: Interventional

Electroconvulsive therapy (ECT), is considered the most effective treatment for severe treatment resistant major depressive disorder (MDD), but it requires about 3 weeks of treatments and can cause considerable acute deficits in memory. It would be a major advance in treatment if ECT could work faster with fewer treatments and result in decrease incidence of memory problems. Ketamine is an excellent candidate for augmentation of ECT because of its acute effects on depression, its short half-life, and its safety profile when given at low doses. Ketamine is given as an infusion and could easily be incorporated into the routine management of patients undergoing ECT, but has never been evaluated prospectively in this context. The investigators propose to assess the efficacy, feasibility, tolerability and safety of N-methyl-D-aspartate antagonist augmentation of ECT using ketamine.

NCT ID: NCT01239888 Recruiting - Depression Clinical Trials

Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study

Start date: January 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone ad-on can induce a response to antidepressants in patients with treatment resistant depression.

NCT ID: NCT01213121 Recruiting - Bipolar Depression Clinical Trials

Neurophysiologic Changes in Patients With Bipolar Depression

Start date: September 2010
Phase: Phase 4
Study type: Interventional

- To examine differences in neurophysiologic parameters between unmedicated patients with bipolar depression and healthy controls - To examine within-subject changes in neurophysiologic parameters in patients with bipolar depression treated with quetiapine

NCT ID: NCT01204346 Recruiting - Depression Clinical Trials

Mentalization - Based Treatment: Adolescents With Co-morbid Depression and Personality Disorder

MBT
Start date: December 2010
Phase: N/A
Study type: Interventional

Mentalisation based treatment (MBT) for young people with co-morbid depression and emerging personality disorder will be more effective in a day/inpatient setting than treatment as usual.